Physician profile
Paul E Raber
NPI 1740394428
$3,817.26
in general payments reported to CMS, 2019-2025
37 companies · $605 in 2025
The $605 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $604 · 2022: $857 · 2023: $863 · 2024: $889 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,356.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $697.01 | 2023-2024 | Accrufer |
| Novo Nordisk INC | $520.15 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $499.59 | 2021-2025 | |
| Lilly USA, LLC | $367.60 | 2021-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $199.97 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $155.52 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.28 | 2021-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company Ltd. | $120.81 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $111.59 | 2023-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $110.83 | 2021-2023 | Trintellix |
| Pfizer INC. | $90.99 | 2022-2025 | |
| Glaxosmithkline, LLC. | $86.22 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Dexcom, INC. | $70.74 | 2021-2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $55.98 | 2024-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $54.65 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $53.06 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $51.72 | 2022-2024 | Quviviq |
| Esperion Therapeutics, INC. | $44.90 | 2024-2025 | Nexletol |
| Vanda Pharmaceuticals INC. | $41.41 | 2021-2025 | Fanapt |
| Kaleo, INC. | $31.70 | 2021 | |
| Senseonics, Incorporated | $25.56 | 2025 | Eversense |
| Amgen INC. | $23.13 | 2023 | Otezla, Repatha |
| Amneal Pharmaceuticals LLC | $22.54 | 2023 | Unithroid |
| Xeris Pharmaceuticals, INC. | $20.20 | 2023 | Gvoke Hypopen |
| Astellas Pharma US INC | $19.88 | 2024 | Veozah |
| Biohaven Pharmaceuticals, INC. | $19.86 | 2021 | |
| Sumitomo Pharma America, INC. | $19.41 | 2025 | Gemtesa |
| Scynexis, INC. | $19.10 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.22 | 2022 | |
| Medtronic, INC. | $16.14 | 2023 | Closurefast |
| Axsome Therapeutics, INC. | $16.12 | 2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $15.71 | 2022 | |
| Abbott Laboratories | $14.74 | 2025 | Freestyle Libre 3 |
| Supernus Pharmaceuticals, INC. | $14.52 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.24 | 2021 | |
| Eisai INC. | $12.72 | 2021 | |
| Sanofi Pasteur INC. | $12.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Raber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.